CLEVELAND–(BUSINESS WIRE)–Medical device and technology company Lazurite(TM) Holdings LLC announced today that it has been selected to participate in the MedTech Innovator 2022 Road Tour Mid-Stage pitch event in Boston, May 10-11. The event will take place at the Boston Convention and Exhibition Center, co-located with Device Talks Boston.
Lazurite’s new ArthroFree(TM) Wireless Surgical Camera System recently became the first such system to receive 510(k) market clearance from the Food and Drug Administration (FDA). The ArthroFree System incorporates Lazurite’s proprietary low-heat, high-intensity Meridiem(TM) light technology along with advanced camera, battery, and wireless transmission technologies. It is designed to deliver improved operating room productivity, patient safety, and economic value through cost-savings, energy efficiency, and reduced setup/breakdown times. The modular system also is designed to be drop-in compatible with patient data consoles, surgical displays and endoscopes found in minimally invasive operating rooms.
The MedTech Innovator Mid-Stage event will feature 30 startup companies that are more advanced, generally having completed a series B or later of funding. Each company will present in two different venues. They will pitch five times in a small group setting to multiple rounds of investors, strategics, and other industry stakeholders during a half day on May 10. Each company will also give a 5-minute pitch to the Device Talks audience on either May 10 or May 11. Five companies will be selected from these presentations to compete for a cash award by the vote of the Device Talks conference audience on their main stage.
About MedTech Innovator
MedTech Innovator is the industry’s nonprofit global competition and accelerator for medical device, digital health and diagnostic companies. Its mission is to improve the lives of patients by accelerating the growth of companies that are transforming the healthcare system. In 2022, MedTech Innovator will hold events, competitions and showcases at JP Morgan Healthcare in San Francisco; the Wilson Sonsini Medical Device Conference in San Francisco; The MedTech Strategist in Dublin, Ireland and San Francisco; Device Talks in Boston; AdvaMed’s The MedTech Conference in Boston; and ApacMed’s MedTech Forum in Singapore.
About Lazurite
Lazurite (formerly Indago) is a pre-revenue medical device startup company backed by private capital. The company has raised more than $18 million to date from institutional investors, family offices, and more than 50 physician champions. The Cleveland-based company (est. 2015) designs devices to set new operating-room standards for efficiency and patient safety. Lazurite’s ArthroFree(TM) System is the first wireless surgical camera system to receive FDA market clearance for broader endoscopic use. The ArthroFree System enables surgical visualization in minimally invasive surgery without the camera and light wires implicated in patient infections, burns, and costly post-operative care. Lazurite’s current product pipeline includes devices that incorporate their patented camera technology and laser light technology. Lazurite’s technologies are protected by a comprehensive intellectual property portfolio encompassing the ArthroFree wireless surgical camera system and the novel Meridiem light source as well as other products currently in development. For more information, see: https://lazurite.co.
Forward Looking Statements
This press release includes “forward-looking statements.” Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will,” “designed,” “milestone,” and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding the expected impact of the ArthroFree System on the field of minimally invasive surgery and our future sales of the ArthroFree System. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Lazurite(TM), ArthroFree(TM), and Meridiem(TM) are trademarks of Lazurite Holdings LLC.
Media Center
Visit lazurite.co/mediafor videos, logos, images, fact sheets, bios and more.
CLEVELAND–(BUSINESS WIRE)– #FDA–Lazurite has been selected to participate in the MedTech Innovator 2022 Road Tour Mid-Stage pitch event, May 10-11 in Boston.